Largest Pharma & Biotech Companies by Country 2026

Updated: August 2026 | Revenue threshold: approximately US$1 billion

Which countries have the largest pharmaceutical and biotechnology companies in 2026? The United States remains the world's dominant center for large pharmaceutical and biotech companies, but China, Japan, Switzerland, the United Kingdom, Germany, India, France, Denmark, South Korea and other countries have developed major global pharmaceutical businesses.

This guide ranks major pharmaceutical and biotechnology companies by country and incorporates revenue in US dollars as the principal size metric. It covers innovative pharmaceutical companies, biotechnology companies, generics manufacturers, biosimilar companies, biologics specialists and selected pharmaceutical CDMOs.

2026 data definition: Revenue figures are the latest available annual or trailing-12-month figures available during 2026. Because companies report on different fiscal calendars, revenue periods are not perfectly synchronized. TTM figures and reported fiscal-year figures are therefore identified separately where appropriate.

Global Pharma & Biotech Revenue Leaders in 2026

The current public-company pharmaceutical universe contains hundreds of listed companies. A broad pharmaceutical-market dataset currently tracks approximately 747 publicly traded companies with combined TTM revenue of about US$2.025 trillion. 

However, broad financial databases can include pharmacies, distributors, medical-device companies, CROs and other healthcare businesses. This article therefore focuses on companies whose businesses are materially connected to pharmaceuticals or biotechnology.

Rank	Company	Country	Revenue	Ticker	Primary Focus
1	Johnson & Johnson	🇺🇸 United States	~US$96B	JNJ	Pharma, oncology, immunology
2	Roche	🇨🇭 Switzerland	~US$80B	ROG.SW	Oncology, immunology, diagnostics
3	Eli Lilly	🇺🇸 United States	US$72.24B	LLY	Diabetes, obesity, oncology
4	Merck & Co.	🇺🇸 United States	~US$66B	MRK	Oncology, vaccines
5	Pfizer	🇺🇸 United States	~US$63B	PFE	Vaccines, oncology, specialty medicines
6	AstraZeneca	🇬🇧 United Kingdom	~US$60B	AZN	Oncology, respiratory, cardiovascular
7	Novartis	🇨🇭 Switzerland	~US$57B	NVS	Oncology, cardiovascular, immunology
8	Sanofi	🇫🇷 France	~US$55B	SNY	Vaccines, immunology
9	Bayer	🇩🇪 Germany	~US$53B	BAYN.DE	Pharmaceuticals, cardiovascular
10	Novo Nordisk	🇩🇰 Denmark	US$51.37B	NVO / NOVO-B	Diabetes, obesity

Revenue values are rounded where the underlying source is not a directly comparable TTM figure. Current TTM data confirms Eli Lilly at US$72.24B and Novo Nordisk at US$51.37B in August 2026. 

🇺🇸 United States: Largest Pharma & Biotech Companies

The United States has the deepest concentration of large pharmaceutical and biotechnology companies, particularly in innovative medicines, oncology, immunology, metabolic disease, gene therapy and advanced biologics.

Company	Revenue	Ticker	Focus	Status
Johnson & Johnson	~US$96B	JNJ	Pharma, oncology, immunology	Public
Eli Lilly	US$72.24B	LLY	Diabetes, obesity, oncology	Public
Merck & Co.	~US$66B	MRK	Oncology, vaccines	Public
Pfizer	~US$63B	PFE	Vaccines, oncology	Public
AbbVie	~US$63B	ABBV	Immunology, oncology	Public
Bristol Myers Squibb	~US$48B	BMY	Oncology, immunology	Public
Amgen	~US$37B	AMGN	Oncology, inflammation	Public
Gilead Sciences	~US$30B	GILD	HIV, oncology, liver disease	Public
Regeneron	~US$15B	REGN	Immunology, ophthalmology, oncology	Public
Viatris	~US$15B	VTRS	Generics, biosimilars	Public
Vertex Pharmaceuticals	~US$12B	VRTX	Genetic disease, pain	Public
Organon	~US$6B	OGN	Women's health, biosimilars	Public
BeOne Medicines	~US$6B	ONC	Oncology	Public
Incyte	~US$5B	INCY	Oncology, immunology	Public
Alnylam Pharmaceuticals	~US$4B	ALNY	RNAi therapeutics	Public
BioMarin	~US$3B	BMRN	Rare disease	Public
Moderna	~US$2B	MRNA	mRNA vaccines/therapeutics	Public
Sarepta Therapeutics	~US$2B	SRPT	Genetic medicines	Public
Exelixis	~US$2.4B	EXEL	Oncology	Public

🇨🇳 China: Major Pharma & Biotech Companies

Company	Revenue	Ticker	Focus	Status
Sinopharm Group	~US$82B	1099.HK	Pharma/distribution	Public
China Resources Pharmaceutical	~US$39B	3320.HK	Pharma/distribution	Public
Guangzhou Baiyunshan	~US$11B	600332.SS	Pharmaceuticals/TCM	Public
WuXi AppTec	~US$6.5B	2359.HK	CRO/CDMO	Public
Huadong Medicine	~US$6.2B	000963.SZ	Pharma/biologics	Public
Fosun Pharma	US$5.92B	600196.SS	Pharma/oncology	Public
Jiangsu Hengrui Medicine	~US$4.6B	600276.SS	Oncology, immunology	Public
CSPC Pharmaceutical	~US$4.4B	1093.HK	Oncology, CNS	Public
Sino Biopharmaceutical	~US$3.9B	1177.HK	Oncology, liver disease	Public
WuXi Biologics	~US$3.1B	2269.HK	Biologics CDMO	Public
Hansoh Pharmaceutical	~US$2.1B	3692.HK	Oncology, CNS, metabolic	Public
Innovent Biologics	~US$1.9B	1801.HK	Oncology, immunology	Public

🇨🇭 Switzerland

Company	Revenue	Ticker	Focus
Roche	~US$80B	ROG.SW	Oncology, immunology, diagnostics
Novartis	~US$57B	NOVN.SW	Oncology, cardiovascular, immunology
Sandoz	~US$11B	SDZ.SW	Generics, biosimilars
Lonza	~US$8B	LONN.SW	Biologics/CDMO
Galderma	~US$5B	GALD.SW	Dermatology/aesthetics
Siegfried Holding	~US$1.7B	SFZN.SW	Pharma CDMO

🇯🇵 Japan

Company	Revenue	Ticker	Focus
Takeda Pharmaceutical	~US$30B	TAK	GI, oncology, rare disease
Otsuka Holdings	~US$14.5B	4578.T	CNS, oncology
Astellas Pharma	~US$11B	4503.T	Oncology, immunology
Daiichi Sankyo	~US$11B	4568.T	Oncology, ADCs
Chugai Pharmaceutical	~US$7B	4519.T	Oncology, immunology
Eisai	~US$5B	4523.T	Neuroscience, oncology
Ono Pharmaceutical	~US$3.4B	4528.T	Oncology, immunology
Kyowa Kirin	~US$3.2B	4151.T	Rare disease, immunology
Shionogi	~US$3B	4507.T	Infectious disease
Santen Pharmaceutical	~US$2B	4536.T	Ophthalmology

🇬🇧 United Kingdom

Company	Revenue	Ticker	Focus
AstraZeneca	~US$60B	AZN	Oncology, respiratory, cardiovascular
GSK	~US$44B	GSK	Vaccines, respiratory, HIV
Hikma Pharmaceuticals	~US$3.3B	HIK	Generics/injectables
Royalty Pharma	~US$2.4B	RPRX	Biopharma royalties

🇩🇪 Germany

Company	Revenue	Ticker	Focus
Bayer	~US$53B	BAYN.DE	Pharma, cardiovascular
Merck KGaA	~US$25B	MRK.DE	Pharma, biotech, life science
BioNTech	~US$3.3B	BNTX	mRNA, oncology
Dermapharm	~US$1.4B	DMP.DE	Dermatology
Boehringer Ingelheim	>$30B*	Private	Human pharma, animal health

*Private-company figures can follow different reporting definitions and should be verified against the company's latest annual report before inclusion in a quantitative ranking.

🇩🇰 Denmark

Company	Revenue	Ticker	Focus
Novo Nordisk	US$51.37B	NVO / NOVO-B	Diabetes, obesity
Lundbeck	~US$4B	HLUN-B.CO	Neuroscience
Genmab	~US$4B	GMAB	Antibody oncology
Zealand Pharma	~US$1.5B	ZEAL.CO	Metabolic disease
ALK-Abelló	~US$1B	ALK-B.CO	Allergy immunotherapy

🇮🇳 India

India is one of the world's most important pharmaceutical manufacturing centers. Its major companies span generics, APIs, specialty medicines, biosimilars and increasingly innovative therapies.

Company	Revenue	Ticker	Focus
Sun Pharmaceutical	~US$6.4B	SUNPHARMA.NS	Specialty pharma, generics, oncology, dermatology
Aurobindo Pharma	~US$4B	AUROPHARMA.NS	Generics, APIs
Dr. Reddy's Laboratories	US$3.58B FY26	RDY	Generics, APIs
Zydus Lifesciences	~US$3B	ZYDUSLIFE.NS	Generics, vaccines
Cipla	~US$3B	CIPLA.NS	Respiratory, generics
Lupin	~US$3B	LUPIN.NS	Generics, respiratory
Biocon	~US$1.9B	BIOCON.NS	Biologics, biosimilars
Glenmark Pharmaceuticals	~US$1.9B	GLENMARK.NS	Specialty pharma
Alkem Laboratories	~US$1.6B	ALKEM.NS	Generics
Mankind Pharma	~US$1.5B	MANKIND.NS	Generics/consumer health
Torrent Pharmaceuticals	~US$1.5B	TORNTPHARM.NS	Cardiology/CNS
Divi's Laboratories	~US$1.2B	DIVISLAB.NS	APIs/CDMO
Piramal Pharma	~US$1.1B	PPLPHARMA.NS	CDMO/specialty pharma
Ipca Laboratories	~US$1.1B	IPCALAB.NS	Generics

Sun Pharma reported FY2026 Indian revenue of approximately ₹192.9 billion and described itself as India's largest pharmaceutical company. Dr. Reddy's reported consolidated FY2026 revenue of ₹335.933 billion, equivalent to approximately US$3.58 billion in its annual report. 

🇫🇷 France

Company	Revenue	Ticker	Focus
Sanofi	~US$55B	SNY	Vaccines, immunology
Ipsen	~US$4.6B	IPN.PA	Oncology, rare disease
Virbac	~US$1.7B	VIRP.PA	Animal health
Servier	>$1B*	Private	Oncology, cardiovascular
Pierre Fabre	>$1B*	Private	Dermatology, oncology

🇮🇱 Israel

Company	Revenue	Ticker	Focus
Teva Pharmaceutical Industries	~US$17B	TEVA	Generics, specialty pharma

🇧🇪 Belgium

Company	Revenue	Ticker	Focus
UCB	~US$9B	UCB.BR	Immunology, neurology
Galapagos	~US$1.2B	GLPG	Immunology

🇪🇸 Spain

Company	Revenue	Ticker	Focus
Grifols	~US$8.5B	GRF.MC	Plasma-derived medicines
Almirall	~US$1.6B	ALM.MC	Dermatology

🇮🇹 Italy

Company	Revenue	Ticker	Focus
Recordati	~US$3.1B	REC.MI	Rare disease, specialty pharma
Chiesi Farmaceutici	>$1B*	Private	Respiratory, rare disease
Menarini Group	>$1B*	Private	Specialty pharma

🇰🇷 South Korea

Company	Revenue	Ticker	Focus
Celltrion	~US$3B	068270.KS	Biosimilars, biologics
Samsung Biologics	>$1B	207940.KS	Biologics CDMO
Yuhan	~US$1.5B	000100.KS	Pharmaceuticals, oncology

🇦🇺 Australia

Company	Revenue	Ticker	Focus
CSL	~US$15B	CSL.AX	Plasma, vaccines, biologics

🇨🇦 Canada

Company	Revenue	Ticker	Focus
Bausch Health	~US$10.5B	BHC	Specialty pharmaceuticals

🇸🇪 Sweden

Company	Revenue	Ticker	Focus
Swedish Orphan Biovitrum (Sobi)	~US$3.1B	SOBI.ST	Rare disease

🇫🇮 Finland

Company	Revenue	Ticker	Focus
Orion	~US$2.2B	ORNAV.HE	Oncology, CNS

🇭🇺 Hungary

Company	Revenue	Ticker	Focus
Gedeon Richter	~US$2.5B	RICHTER.BU	Women's health, CNS

🇿🇦 South Africa

Company	Revenue	Ticker	Focus
Aspen Pharmacare	~US$2.4B	APN.JO	Generics, vaccines

Revenue Tiers: The Global Pharma Landscape

Looking at revenue rather than simply company count reveals several distinct tiers.

• $50B+ Global mega-pharma 
• $10–50B Global large-cap 
• $5–10B Large pharma/biotech 
• $2–5B Mid-large pharma/biotech
• $1–2B Emerging large-scale companies

Which Countries Have the Most Pharma Revenue?

Revenue concentration is different from company count. The United States has several enormous innovative pharmaceutical companies, while Switzerland derives extraordinary pharmaceutical-sector scale from Roche and Novartis.

Denmark's position is also notable: Novo Nordisk alone generates more than US$50 billion of TTM (Trailing Twelve Months) revenue, illustrating how a relatively small country can host a globally dominant pharmaceutical company.

India and China have many companies around the US$1–5 billion range, reflecting their enormous domestic pharmaceutical markets and manufacturing ecosystems.

Pharma vs. Biotech vs. CDMO

A revenue ranking should not treat every company as the same type of business.

• Big Pharma: diversified patented medicines and large commercial portfolios.
• Biotech: biologically derived or highly specialized innovative medicines.
• Generics: lower-cost versions of established medicines.
• Biosimilars: biological alternatives to reference biologic medicines.
• CDMO: companies that develop and manufacture medicines for other pharmaceutical companies.
• CRO: companies providing research and clinical-development services.
• Plasma/biologics: companies specializing in plasma-derived and biological medicines.

For example, WuXi AppTec, WuXi Biologics and Lonza are extremely important life-sciences companies but their economics differ substantially from a company such as Eli Lilly or Merck.

Fastest-Growing Strategic Areas in Pharma 2026

• Obesity and metabolic disease
• Oncology
• Antibody-drug conjugates
• Bispecific antibodies
• Cell therapy
• Gene therapy and gene editing
• RNA therapeutics
• Radiopharmaceuticals
• Rare diseases
• Immunology
• AI-enabled drug discovery
• Biosimilars

Why Revenue Is a Better Starting Point Than Market Cap

Market capitalization reflects what investors believe a company may be worth in the future. Revenue measures the scale of the business that already exists.

Using revenue as the first screen is therefore useful for identifying the world's largest operating pharmaceutical and biotech companies.

However, revenue alone does not tell investors whether a company is attractive.

• High revenue does not guarantee high profit.
• High revenue does not guarantee future growth.
• A patent cliff can rapidly reduce revenue.
• A successful pipeline can transform a smaller biotech.
• Debt can materially change investment risk.
• R&D productivity is critical for long-term pharmaceutical companies.

What Investors Should Compare

After identifying companies with more than US$1 billion in revenue, investors should compare:

1. Revenue growth
2. Operating margin
3. Free cash flow
4. R&D expenditure
5. Pipeline value
6. Patent-expiration exposure
7. Clinical-trial success
8. Debt and interest expense
9. Market capitalization
10. Enterprise value
11. Valuation relative to expected growth

Frequently Asked Questions

What is the largest pharma company by revenue in 2026?

The answer depends on whether diversified healthcare companies are included and whether revenue is measured by fiscal year or TTM. Among major pharmaceutical businesses, Johnson & Johnson, Roche, Eli Lilly, Merck, Pfizer and other global leaders are at the top of the revenue rankings. Current TTM data puts Eli Lilly at approximately US$72.24 billion. :

Which country has the most pharmaceutical companies?

The United States has the deepest concentration of large innovative pharmaceutical and biotechnology companies. China and Japan also have very large pharmaceutical ecosystems, while India has an exceptionally large generics and manufacturing industry.

Which pharmaceutical company has the largest revenue in Denmark?

Novo Nordisk is by far Denmark's largest pharmaceutical company. Its TTM revenue was approximately US$51.37 billion in August 2026. 

Which Indian pharma companies exceed US$1 billion in revenue?

Major examples include Sun Pharmaceutical, Aurobindo Pharma, Dr. Reddy's Laboratories, Zydus Lifesciences, Cipla, Lupin, Biocon, Glenmark, Alkem, Mankind Pharma, Torrent Pharmaceuticals, Divi's Laboratories, Piramal Pharma and Ipca Laboratories.

What was Dr. Reddy's revenue in FY2026?

Dr. Reddy's Laboratories reported consolidated FY2026 revenue of ₹335.933 billion, equivalent to approximately US$3.58 billion in its annual reporting. 

Does this list include private pharmaceutical companies?

Yes, where reliable revenue information is available. Important private companies include Boehringer Ingelheim, Servier, Chiesi Farmaceutici and Menarini Group. Private companies do not have publicly traded market capitalizations.

Data Methodology

Revenue threshold: approximately US$1 billion.

Revenue period: latest reported annual or TTM revenue available in 2026.

Currency: converted to US dollars where necessary. Exchange-rate differences can cause modest variation between sources.

Country: primarily headquarters country.

Market capitalization: separate from revenue and should be date-stamped because it changes continuously.

Classification: pharmaceutical, biotechnology, biologics, generics, biosimilars and selected pharmaceutical CDMO businesses are included. Pure pharmacies, insurers, hospitals and unrelated healthcare companies are excluded.

Important data caveat: A company's revenue may change materially following acquisitions, divestitures, currency movements or reporting-period changes. The US$1 billion threshold should therefore be treated as a dynamic screen rather than a permanent classification.

Sources

• Public-company revenue and market data: CompaniesMarketCap pharmaceutical-company database. 
• Eli Lilly revenue data: current TTM financial data. 
• Novo Nordisk revenue data: current TTM financial data. 
• Sun Pharmaceutical FY2026 Annual Report. 

Bottom Line

The global pharmaceutical and biotechnology industry is dominated by a relatively small number of enormous companies, but the underlying ecosystem is highly diversified.

The United States leads in the number and scale of innovative pharmaceutical and biotechnology companies. Switzerland has extraordinary pharmaceutical revenue concentration through Roche and Novartis. China and Japan have deep domestic pharmaceutical ecosystems, while India is a global powerhouse in generics and pharmaceutical manufacturing.

Denmark demonstrates how a small country can become a global pharmaceutical leader through Novo Nordisk, while South Korea is becoming increasingly important in biologics and biosimilar manufacturing.

For investors, the US$1 billion revenue threshold is only the beginning. The next step is to compare growth, margins, pipeline quality, patent risk, R&D productivity, balance-sheet strength and valuation.

OneDayAdvisor takeaway: Revenue identifies the world's largest pharmaceutical and biotechnology businesses. It does not automatically identify the best investments. Use revenue as the first screening layer, then evaluate growth, competitive advantage, pipeline quality, financial strength and valuation.

Disclaimer: This article is for educational and informational purposes only and is not investment advice. Revenue figures, market capitalizations, company classifications and rankings can change. Verify current company filings and market prices before making investment decisions.

[1]: https://companiesmarketcap.com/eli-lilly/revenue/ "Eli Lilly (LLY) - Revenue"